Repligen (NASDAQ:RGEN) Shares Up 6.1% – Should You Buy?

Shares of Repligen Co. (NASDAQ:RGEN) were up 6.1% during mid-day trading on Wednesday . The company traded as high as $136.85 and last traded at $136.27. Approximately 327,141 shares traded hands during mid-day trading, a decline of 51% from the average daily volume of 667,443 shares. The stock had previously closed at $128.49.

Wall Street Analyst Weigh In

RGEN has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target on the stock. Finally, UBS Group lowered their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 6.65. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -373.83, a P/E/G ratio of 3.75 and a beta of 0.96. The firm has a 50-day simple moving average of $140.30 and a two-hundred day simple moving average of $143.67.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.23 EPS. On average, sell-side analysts anticipate that Repligen Co. will post 1.52 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Andra AP fonden acquired a new stake in Repligen in the second quarter worth $25,000. Lazard Asset Management LLC boosted its holdings in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the last quarter. UMB Bank n.a. increased its stake in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV purchased a new position in shares of Repligen in the third quarter valued at about $37,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.